BioPharma, Artificial Intelligence Recursion Vets Unveil Startup Noetik, Using AI to Unlock Tumor Biology By Frank Vinluan
Artificial Intelligence, BioPharma Nvidia’s $50M Recursion Investment Starts Alliance to Scale Up in AI Drug Discovery By Frank Vinluan
Artificial Intelligence, BioPharma AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions By Frank Vinluan
Artificial Intelligence, Startups, BioPharma Recursion raises $239M in Series D, partners with lead investor Bayer By Alaric DeArment
BioPharma, Startups, Artificial Intelligence AI drug discovery company Recursion Pharmaceuticals raises $121M Series C By Kevin Truong
Artificial Intelligence, BioPharma Already Partnered With Nvidia, Iambic Adds $100M for AI Drug Discovery By Frank Vinluan
Sponsored Post 4 Ways Biopharma Is Applying AI/ML to Improve Drug Development Outcomes By Stephanie Baum
Artificial Intelligence, BioPharma RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease By Frank Vinluan
BioPharma, Artificial Intelligence Biotech startup with AlphaGo-type AI approach snags $30M By Arundhati Parmar
BioPharma, Pharma, Artificial Intelligence Bayer reloads Leaps with €1.3 billion to step up investments in biotech innovation By Frank Vinluan
BioPharma, Artificial Intelligence Cell therapy, AI drug discovery highlight 2021’s record year in biotech IPOs By Frank Vinluan
